Drug intelligence / Profile preview

FM-601

Development stage: Phase 2
Lead developer: C. B. Fleet
Modality: Small Molecules
Administration: Oral

Overview

**FM-601** was an investigational liquid bowel-cleansing product developed by C.B. Fleet for administration before elective colonoscopy. It was evaluated in a completed Phase 2 dose-escalation study in adults aged 50 years and older to determine an efficacious dose range for pre-procedural bowel preparation. Its precise active-ingredient composition, molecular target, and detailed pharmacologic mechanism were not publicly disclosed in the available trial record.

Other names: FM-601FM601FM 601

Targets

JAK3 (Janus kinase 3)BTK (Bruton tyrosine kinase)BMX (Bone Marrow Tyrosine Kinase X-linked)

Beyond the preview

Go deeper on FM-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FM-601.

Explore the full profile